Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson’s Disease Dual Target Ligands

BACKGROUND Virtual methodologies have become essential components of the drug discovery pipeline. Specifically, structure-based drug design methodologies exploit the 3D structure of molecular targets to discover new drug candidates through molecular docking. Recently, dual target ligands of the Adenosine A2A Receptor and Monoamine Oxidase B enzyme have been proposed as effective therapies for the treatment of Parkinson's disease. METHODS In this paper we propose a structure-based methodology, which is extensively validated, for the discovery of dual Adenosine A2A Receptor/Monoamine Oxidase B ligands. This methodology involves molecular docking studies against both receptors and the evaluation of different scoring functions fusion strategies for maximizing the initial virtual screening enrichment of known dual ligands. RESULTS The developed methodology provides high values of enrichment of known ligands, which outperform that of the individual scoring functions. At the same time, the obtained ensemble can be translated in a sequence of steps that should be followed to maximize the enrichment of dual target Adenosine A2A Receptor antagonists and Monoamine Oxidase B inhibitors. CONCLUSION Information relative to docking scores to both targets have to be combined for achieving high dual ligands enrichment. Combining the rankings derived from different scoring functions proved to be a valuable strategy for improving the enrichment relative to single scoring function in virtual screening experiments.

[1]  D. Frank Hsu,et al.  Consensus Scoring Criteria for Improving Enrichment in Virtual Screening , 2005, J. Chem. Inf. Model..

[2]  Stephani Joy Y Macalino,et al.  Role of computer-aided drug design in modern drug discovery , 2015, Archives of Pharmacal Research.

[3]  Hanoch Senderowitz,et al.  SeleX-CS: A New Consensus Scoring Algorithm for Hit Discovery and Lead Optimization , 2009, J. Chem. Inf. Model..

[4]  Georgios Archontis,et al.  Structure based inhibitor design targeting glycogen phosphorylase B. Virtual screening, synthesis, biochemical and biological assessment of novel N-acyl-β-d-glucopyranosylamines. , 2014, Bioorganic & medicinal chemistry.

[5]  Thomas J. Crisman,et al.  Which aspects of HTS are empirically correlated with downstream success? , 2008, Current opinion in drug discovery & development.

[6]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[7]  Luhua Lai,et al.  Further development and validation of empirical scoring functions for structure-based binding affinity prediction , 2002, J. Comput. Aided Mol. Des..

[8]  Tian Zhu,et al.  Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. , 2013, Journal of medicinal chemistry.

[9]  Leonardo L. G. Ferreira,et al.  Molecular Docking and Structure-Based Drug Design Strategies , 2015, Molecules.

[10]  Chang-Guo Zhan,et al.  Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening. , 2015, Journal of medicinal chemistry.

[11]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[12]  Miklos Feher,et al.  Consensus scoring for protein-ligand interactions. , 2006, Drug discovery today.

[13]  Xin Chen,et al.  Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking , 2011, J. Chem. Inf. Model..

[14]  Richard Morphy,et al.  From magic bullets to designed multiple ligands. , 2004, Drug discovery today.

[15]  M. Youdim,et al.  Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases , 2005, Mechanisms of Ageing and Development.

[16]  Shu Liu,et al.  Application of Consensus Scoring and Principal Component Analysis for Virtual Screening against β-Secretase (BACE-1) , 2012, PloS one.

[17]  J. Gaddum,et al.  The Pharmacological Basis of Therapeutics , 1966 .

[18]  M. Cordeiro,et al.  Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs. , 2012, Mini reviews in medicinal chemistry.

[19]  M. Schwarzschild,et al.  Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. , 2003, Bioorganic & medicinal chemistry.

[20]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[21]  Jessica Holien,et al.  Improvements, trends, and new ideas in molecular docking: 2012–2013 in review , 2015, Journal of molecular recognition : JMR.

[22]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[23]  Simona Distinto,et al.  Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection—What can we learn from earlier mistakes? , 2008, J. Comput. Aided Mol. Des..

[24]  Walter Cabri,et al.  Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. , 2013, Journal of medicinal chemistry.

[25]  Maykel Cruz-Monteagudo,et al.  Toward the computer-aided discovery of FabH inhibitors. Do predictive QSAR models ensure high quality virtual screening performance? , 2014, Molecular Diversity.

[26]  Jiro Shimada,et al.  Bootstrap-Based Consensus Scoring Method for Protein-Ligand Docking , 2008, J. Chem. Inf. Model..

[27]  A Lavecchia,et al.  Virtual screening strategies in drug discovery: a critical review. , 2013, Current medicinal chemistry.

[28]  Osmar Norberto de Souza,et al.  Discovery of New Inhibitors of Mycobacterium tuberculosis InhA Enzyme Using Virtual Screening and a 3D-Pharmacophore-Based Approach , 2013, J. Chem. Inf. Model..

[29]  C. Müller,et al.  Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists. , 1997, Journal of medicinal chemistry.

[30]  Neal Castagnoli,et al.  Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease , 2011, Neurotherapeutics.

[31]  Robert P. Sheridan,et al.  Protocols for Bridging the Peptide to Nonpeptide Gap in Topological Similarity Searches , 2001, J. Chem. Inf. Comput. Sci..

[32]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[33]  Werner J Geldenhuys,et al.  Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? , 2007, Parkinsonism & related disorders.

[34]  I. Kuntz,et al.  DOCK 6: combining techniques to model RNA-small molecule complexes. , 2009, RNA.

[35]  Pankaj R. Daga,et al.  Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification , 2014, J. Chem. Inf. Model..

[36]  Kenji Matsuno,et al.  Identification of a New Series of STAT3 Inhibitors by Virtual Screening. , 2010, ACS medicinal chemistry letters.

[37]  M. Natália D. S. Cordeiro,et al.  Harmonization of QSAR Best Practices and Molecular Docking Provides an Efficient Virtual Screening Tool for Discovering New G-Quadruplex Ligands , 2015, J. Chem. Inf. Model..

[38]  Sonja Hinz,et al.  Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones. , 2013, Journal of medicinal chemistry.

[39]  Markus Lill,et al.  Virtual screening in drug design. , 2013, Methods in molecular biology.